Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects, Subjects With Type 1 Diabetes Mellitus, and Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects, Subjects With Type 1 Diabetes Mellitus, and Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs Insulin lispro (Primary) ; MK-1092 (Primary) ; Insulin glargine
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 29 Nov 2018 Status changed from active, no longer recruiting to completed.
    • 29 Oct 2018 Planned End Date changed from 26 Oct 2018 to 30 Oct 2018.
    • 29 Oct 2018 Planned primary completion date changed from 26 Oct 2018 to 30 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top